IN2014KN01075A - - Google Patents

Info

Publication number
IN2014KN01075A
IN2014KN01075A IN1075KON2014A IN2014KN01075A IN 2014KN01075 A IN2014KN01075 A IN 2014KN01075A IN 1075KON2014 A IN1075KON2014 A IN 1075KON2014A IN 2014KN01075 A IN2014KN01075 A IN 2014KN01075A
Authority
IN
India
Prior art keywords
compounds
muscarinic
receptor
16this
agonists
Prior art date
Application number
Inventor
Miles Congreve
Giles Brown
Julie Cansfield
Benjamin Tehan
Original Assignee
Heptares Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heptares Therapeutics Ltd filed Critical Heptares Therapeutics Ltd
Publication of IN2014KN01075A publication Critical patent/IN2014KN01075A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

16This invention relates to compounds that are agonists of the muscarinic M1 receptor and which are useful in the treatment of muscarinic M1 receptor mediated diseases. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula I where n is 1 or 2; p is 0 1 or 2; q is 0 1 or 2; and R R are as defined herein.
IN1075KON2014 2011-11-18 2012-11-16 IN2014KN01075A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161632813P 2011-11-18 2011-11-18
PCT/GB2012/052857 WO2013072705A1 (en) 2011-11-18 2012-11-16 Muscarinic m1 receptor agonists

Publications (1)

Publication Number Publication Date
IN2014KN01075A true IN2014KN01075A (en) 2015-10-09

Family

ID=47278335

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1075KON2014 IN2014KN01075A (en) 2011-11-18 2012-11-16

Country Status (16)

Country Link
US (6) US9187451B2 (en)
EP (1) EP2780015B1 (en)
JP (2) JP6083818B2 (en)
CN (2) CN106831541B (en)
AU (3) AU2012338581B2 (en)
BR (1) BR112014012056B1 (en)
CA (1) CA2856076C (en)
DK (1) DK2780015T3 (en)
ES (1) ES2619829T3 (en)
GB (1) GB2511685A (en)
HU (1) HUE033114T2 (en)
IN (1) IN2014KN01075A (en)
PL (1) PL2780015T3 (en)
PT (1) PT2780015T (en)
SG (1) SG11201402405QA (en)
WO (1) WO2013072705A1 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6083818B2 (en) 2011-11-18 2017-02-22 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ Muscarinic M1 receptor agonist
DK2897948T3 (en) * 2012-09-18 2016-12-05 Heptares Therapeutics Ltd BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS
GB2519470A (en) * 2013-09-18 2015-04-22 Heptares Therapeutics Ltd Bicyclic aza compounds as muscarinic M1 receptor agonists
PL3102568T3 (en) * 2014-02-06 2019-01-31 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists.
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201504675D0 (en) * 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513742D0 (en) * 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
CN108226319A (en) * 2016-12-22 2018-06-29 亚宝药业集团股份有限公司 A kind of method for detecting optical isomer in Rivastigmine patch
US10501483B2 (en) 2017-10-24 2019-12-10 Allergan, Inc. Enamines and diastereo-selective reduction of enamines
JP6691928B2 (en) * 2018-02-07 2020-05-13 株式会社ジンズホールディングス Eyewear set and signal processing unit
GB201810239D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
CN113121495A (en) * 2020-01-10 2021-07-16 深圳市九明药业有限公司 Preparation method of desloratadine
WO2025167860A1 (en) * 2024-02-06 2025-08-14 南京迈诺威医药科技有限公司 Pharmaceutical composition containing xanomeline or salt thereof

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369184A (en) 1980-01-24 1983-01-18 Janssen Pharmaceutica N.V. 1-(Cyclohexyl)-4-aryl-4-piperidinecarboxylic acid derivatives
JPS56110674A (en) 1980-01-24 1981-09-01 Janssen Pharmaceutica Nv Novel 11*cyclohexyl**44aryll44piperidine carboxylic acid derivative
US5852029A (en) 1990-04-10 1998-12-22 Israel Institute For Biological Research Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
GB9300194D0 (en) 1993-01-06 1993-03-03 Wyeth John & Brother Ltd Piperazine derivatives
US5446051A (en) 1994-05-31 1995-08-29 Eli Lilly And Company Aryl-spaced decahydroisoquinoline-3-carboxylic acids as excitatory amino acid receptor antagonists
CA2200468A1 (en) 1994-10-27 1996-05-09 Wayne J. Thompson Muscarine antagonists
IL117149A0 (en) 1995-02-23 1996-06-18 Schering Corp Muscarinic antagonists
US5889006A (en) 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
WO1997016187A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Muscarine antagonists
US5854245A (en) * 1996-06-28 1998-12-29 Merck & Co., Inc. Fibrinogen receptor antagonists
US6664258B1 (en) 1996-08-26 2003-12-16 Pfizer Inc Spirocyclic dopamine receptor subtype ligands
CA2293408A1 (en) 1997-06-18 1998-12-23 Merck & Co., Inc. Alpha 1a adrenergic receptor antagonists
GB9715892D0 (en) 1997-07-29 1997-10-01 Zeneca Ltd Heterocyclic compounds
AU2095099A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Phthalimide-piperidine, -pyrrolidine and -azepine derivatives, their preparationand their use as muscarinic receptor (ant-)agonists
WO1999032489A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
AU2307899A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
WO1999032481A1 (en) 1997-12-23 1999-07-01 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
CZ286152B6 (en) 1998-03-13 2000-01-12 Miroslav Ing. Csc. Vlček Transparent and semitransparent diffraction elements, particularly holograms and process of their production
HUP0101511A3 (en) * 1998-04-28 2002-12-28 Dainippon Pharmaceutical Co 1-[(1-substituted-4-piperidinyl)methyl]-4-piperidine derivatives, process for producing the same, medicinal compositions containing the same and intermediates of these compounds
US6387930B1 (en) 1999-05-04 2002-05-14 Schering Corporation Piperidine derivatives useful as CCR5 antagonists
EP1175224B1 (en) 1999-05-04 2005-02-23 Schering Corporation Pegylated interferon alfa-ccr5 antagonist combination hiv therapy
EP1175402B1 (en) 1999-05-04 2005-07-20 Schering Corporation Piperidine derivatives useful as ccr5 antagonists
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
HK1048807A1 (en) 1999-09-13 2003-04-17 贝林格尔‧英格海姆药物公司 Novel spiroheterocyclic compounds useful as reversible inhibitors of cysteine proteases
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
WO2001027104A1 (en) 1999-10-13 2001-04-19 Banyu Pharmaceutical Co., Ltd. Substituted imidazolidinone derivatives
US7163938B2 (en) * 2000-11-28 2007-01-16 Eli Lilly And Company Substituted carboxamides
CA2444595A1 (en) 2001-04-20 2002-10-31 Banyu Pharmaceutical Co., Ltd. Benzimidazolone derivatives
BR0210391A (en) 2001-06-12 2004-06-15 Elan Pharm Inc Compound, methods of treating a patient who has or prevent a patient from contracting a disease or condition and preparing a compound, and, using a compound
WO2004089942A2 (en) 2001-10-02 2004-10-21 Acadia Pharmaceuticals Inc. Benzimidazolidinone derivatives as muscarinic agents
GB0128378D0 (en) 2001-11-27 2002-01-16 Smithkline Beecham Plc Novel Compounds
US7550459B2 (en) 2001-12-28 2009-06-23 Acadia Pharmaceuticals, Inc. Tetrahydroquinoline analogues as muscarinic agonists
NZ533566A (en) 2001-12-28 2007-03-30 Acadia Pharm Inc Tetrahydroquinoline analogues as muscarinic agonists
US7256186B2 (en) 2002-02-06 2007-08-14 Schering Corporation Gamma secretase inhibitors
US20040171614A1 (en) 2002-02-06 2004-09-02 Schering-Plough Corporation Novel gamma secretase inhibitors
ATE454381T1 (en) * 2002-03-28 2010-01-15 Mitsubishi Tanabe Pharma Corp BENZOFURAN DERIVATIVE
AU2003242252A1 (en) 2002-06-07 2003-12-22 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives
DE60226906D1 (en) 2002-07-31 2008-07-10 Ranbaxy Lab Ltd 3,6-DISUBSTITUTED AZABICYCLO Ä3.1.0ÜHEXANDERIVATES SUITED AS MUSCARIN RECEPTOR ANTAGONISTS
MXPA05003344A (en) 2002-09-30 2005-11-23 Neurosearch As Novel 1,4-diazabicycloalkane derivatives, their preparation and use.
AU2003293006A1 (en) 2002-11-22 2004-06-18 Japan Tobacco Inc. Fused bicyclic nitrogen-containing heterocycles
CA2507501C (en) 2002-11-27 2011-10-04 Incyte Corporation 3-aminopyrrolidine derivatives as modulators of chemokine receptors
WO2004069828A1 (en) 2003-02-04 2004-08-19 Mitsubishi Pharma Corporation Piperidine compound and medicinal use thereof
EP1647553A4 (en) * 2003-07-17 2008-12-31 Astellas Pharma Inc 2-acylaminothiazole derivative or salt thereof
EP1679069A4 (en) 2003-10-21 2009-05-13 Dainippon Sumitomo Pharma Co Novel piperidine derivative
DE602005013931D1 (en) 2004-02-05 2009-05-28 Schering Corp
JP2007522160A (en) 2004-02-10 2007-08-09 エフ．ホフマン−ラ　ロシュ　アーゲー Chemokine CCR5 receptor modulator
US7488745B2 (en) 2004-07-16 2009-02-10 Schering Corporation Compounds for the treatment of inflammatory disorders
US7504424B2 (en) 2004-07-16 2009-03-17 Schering Corporation Compounds for the treatment of inflammatory disorders
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
JP2008521821A (en) 2004-11-29 2008-06-26 バーテックス ファーマシューティカルズ インコーポレイテッド Muscarinic receptor modulators
JP4774995B2 (en) * 2005-01-12 2011-09-21 アステラス製薬株式会社 Pharmaceutical composition comprising an acylaminothiazole derivative as an active ingredient
WO2006105035A2 (en) 2005-03-28 2006-10-05 Vertex Pharmaceuticals Incorporated Muscarinic modulators
EP1900732A4 (en) 2005-06-24 2009-11-18 Toyama Chemical Co Ltd NOVEL HETEROCYCLIC NITROGENIC COMPOUND AND SALT THEREOF
AU2006330866A1 (en) 2005-12-22 2007-07-05 Vertex Pharmaceuticals Incorporated Modulators of muscarinic receptors
WO2007079164A2 (en) 2005-12-29 2007-07-12 Abbott Laboratories Protein kinase inhibitors
RU2008137583A (en) 2006-02-22 2010-03-27 Вертекс Фармасьютикалз Инкорпорейшн (Us) SPIROPIPERIDINES AS MODULATORS OF MUSCARINE RECEPTORS
RU2008137593A (en) 2006-02-22 2010-03-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) MUSCARINE RECEPTOR MODULATORS
EP2051712A2 (en) 2006-08-15 2009-04-29 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
MX2009006756A (en) 2006-12-22 2009-06-30 Novartis Ag 1-aminomethyl- l- phenyl- cyclohexane derivatives as ddp-iv inhibitors.
WO2008117229A1 (en) 2007-03-23 2008-10-02 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
UY31672A1 (en) * 2008-02-28 2009-09-30 "MUSCARINIC RECEPTORS AGONISTS PHARMACEUTICAL COMPOSITIONS METHODS OF TREATMENT OF THE SAME, AND PROCEDURES FOR THEIR PREPARATION"
AU2009228931B2 (en) 2008-03-27 2013-05-23 Janssen Pharmaceutica Nv Aza-bicyclohexyl substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
MX2011004340A (en) 2008-10-29 2011-05-23 Gruenenthal Gmbh Substituted spiroamines.
CN102256963B (en) * 2008-12-19 2014-06-11 贝林格尔.英格海姆国际有限公司 Cyclic pyrimidine-4-carboxamides as CCR2 receptor antagonists for the treatment of inflammation, asthma and COPD
KR20120006544A (en) 2009-04-17 2012-01-18 얀센 파마슈티카 엔.브이. 4-azetidinyl-1-phenyl-cyclohexane antagonist of CCR2
FR2945531A1 (en) 2009-05-12 2010-11-19 Sanofi Aventis 7-AZA-SPIRO® 3,5-NONANE-7-CARBOXYLATE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
WO2011112825A2 (en) 2010-03-10 2011-09-15 Vanderbilt University Heterocyclyl-azabicyclo[3.2.1]octane analogs as selective m1 agonists and methods of making and using same
EP2560962B1 (en) 2010-04-22 2015-05-20 Janssen Pharmaceutica NV Indazole compounds useful as ketohexokinase inhibitors
WO2011137012A1 (en) 2010-04-27 2011-11-03 Merck Sharp & Dohme Corp. Prolylcarboxypeptidase inhibitors
EP2568812B1 (en) 2010-05-11 2016-10-26 Merck Sharp & Dohme Corp. Novel prolylcarboxypeptidase inhibitors
EP2576520A1 (en) 2010-05-28 2013-04-10 GE Healthcare UK Limited Radiolabeled compounds and methods thereof
KR20130099970A (en) 2010-09-17 2013-09-06 어레이 바이오파마 인크. Piperidinyl-substituted lactams as gpr119 modulators
US20140005165A1 (en) 2011-03-17 2014-01-02 Anilkumar G. Nair Substituted 3-azabicyclo[3.1.0]hexane derivatives useful as ccr2 antagonists
JP2013010719A (en) 2011-06-30 2013-01-17 Dainippon Sumitomo Pharma Co Ltd Benzimidazolone and oxindole derivative, and pharmaceutical application of them
JP6083818B2 (en) 2011-11-18 2017-02-22 ヘプタレス セラピューティクス リミテッドＨｅｐｔａｒｅｓ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ Muscarinic M1 receptor agonist
DK2897948T3 (en) 2012-09-18 2016-12-05 Heptares Therapeutics Ltd BICYCLIC AZA RELATIONS AS MUSCARIN M1 RECEPTOR AGONISTS
ES2694299T3 (en) 2013-02-07 2018-12-19 Heptares Therapeutics Limited Piperidin-1-yl and azepin-1-yl carboxylates as agonists of the M4 muscarinic receptor
PL3102568T3 (en) 2014-02-06 2019-01-31 Heptares Therapeutics Limited Bicyclic aza compounds as muscarinic m1 receptor agonists.
GB201404922D0 (en) 2014-03-19 2014-04-30 Heptares Therapeutics Ltd Pharmaceutical compounds
NZ734400A (en) 2015-02-13 2018-03-23 Suven Life Sciences Ltd Amide compounds as 5-ht4 receptor agonists
GB201504675D0 (en) 2015-03-19 2015-05-06 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201513743D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201513740D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonist
GB201513742D0 (en) 2015-08-03 2015-09-16 Heptares Therapeutics Ltd Muscarinic agonists
GB201519352D0 (en) 2015-11-02 2015-12-16 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201617454D0 (en) 2016-10-14 2016-11-30 Heptares Therapeutics Limited Pharmaceutical compounds
US10259787B2 (en) 2016-10-14 2019-04-16 Heptares Therapeutics Limited Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
GB201709652D0 (en) 2017-06-16 2017-08-02 Heptares Therapeutics Ltd Pharmaceutical compounds
US10501483B2 (en) 2017-10-24 2019-12-10 Allergan, Inc. Enamines and diastereo-selective reduction of enamines
GB201810239D0 (en) * 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201810245D0 (en) 2018-06-22 2018-08-08 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819960D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB201819961D0 (en) 2018-12-07 2019-01-23 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202020191D0 (en) 2020-12-18 2021-02-03 Heptares Therapeutics Ltd Pharmaceutical compounds
GB202103211D0 (en) 2021-03-08 2021-04-21 Heptares Therapeutics Ltd Pharmaceutical compounds for use in therapy

Also Published As

Publication number Publication date
AU2018236871B2 (en) 2020-02-27
JP2017095501A (en) 2017-06-01
HK1201737A1 (en) 2015-09-11
US20200253982A1 (en) 2020-08-13
HUE033114T2 (en) 2017-11-28
US20160068508A1 (en) 2016-03-10
AU2018236871A1 (en) 2018-10-18
GB201410398D0 (en) 2014-07-23
AU2017201505A1 (en) 2017-03-23
CN106831541B (en) 2019-09-06
CA2856076A1 (en) 2013-05-23
JP2015501799A (en) 2015-01-19
DK2780015T3 (en) 2017-03-27
WO2013072705A1 (en) 2013-05-23
EP2780015A1 (en) 2014-09-24
SG11201402405QA (en) 2014-09-26
BR112014012056B1 (en) 2021-12-14
US10973832B2 (en) 2021-04-13
BR112014012056A2 (en) 2020-10-27
US20170157139A1 (en) 2017-06-08
US9907805B2 (en) 2018-03-06
AU2017201505B2 (en) 2018-10-25
BR112014012056A8 (en) 2017-06-20
US11793817B2 (en) 2023-10-24
US20140329803A1 (en) 2014-11-06
CN104039321B (en) 2017-02-22
AU2012338581B2 (en) 2016-12-08
US10413553B2 (en) 2019-09-17
JP6404374B2 (en) 2018-10-10
JP6083818B2 (en) 2017-02-22
ES2619829T3 (en) 2017-06-27
CN104039321A (en) 2014-09-10
US9573929B2 (en) 2017-02-21
PT2780015T (en) 2017-03-23
CA2856076C (en) 2020-02-25
AU2012338581A1 (en) 2014-06-05
CN106831541A (en) 2017-06-13
EP2780015B1 (en) 2017-01-04
US20210353637A1 (en) 2021-11-18
US9187451B2 (en) 2015-11-17
GB2511685A (en) 2014-09-10
PL2780015T3 (en) 2017-06-30
US20180153900A1 (en) 2018-06-07

Similar Documents

Publication Publication Date Title
IN2014KN01075A (en)
CA2883210C (en) Bicyclic aza compounds as muscarinic m1 receptor agonists
MX2020010674A (en) Muscarinic receptor agonists.
MX2013004329A (en) Substituted 6-amino-nicotinamides as kcnq2/3 modulators.
MD20150035A2 (en) Bruton's tyrosine kinase inhibitors
MX344530B (en) Substituted benzene compounds.
EP2582676A4 (en) POSITIVE ALLOSTERIC MODULATORS OF M1 RECEPTOR OF TETRAHYDROQUINOLINE AMIDE
TN2012000231A1 (en) Quinoline amide m1 receptor positive allosteric modulators
MX2020010535A (en) Methods of treating cancer.
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
IN2014MN00988A (en)
IN2015DN01119A (en)
MY160075A (en) Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
IN2014CN02273A (en)
IN2014MN00697A (en)
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2014000964A (en) Substituted heterocyclic aza derivatives.
PH12014502623B1 (en) Difluoro-hexahydro-cyclopentaoxazinyls and difluoro-hexahydro-benzooxazinyls as bace1 inhibitors
MX2013002118A (en) Substituted 2-oxy-quinoline-3-carboxamides as kcnq2/3 modulators.
IN2013DN02555A (en)
MX2014001862A (en) 5-cycloalkyl- or 5-heterocyclyl-nicotinamides.
MX2013002119A (en) Substituted 2-oxo- and 2-thioxo-dihydroquinoline-3-carboxamides as kcnq2/3 modulators.
IN2014DN03010A (en)
MX2013006670A (en) 2-carboxamide-4-piperazinyl-benzofuran derivative.